Looking For a Doctor or Facility?

Find a Doctor

Need Help?

Contact

Live Chat

FDA Approved 46 Novel Drugs in 2017

Zafeira Sarrimanolis
Zafeira Sarrimanolis, PharmD, MedCost Clinical Consultant

FDA Approved 46 Novel Drugs in 2017

In 2016 we saw 22 brand-new novel drugs hit the market. This year the FDA has approved 46 novel drugs.

A novel drug is an innovative product with a chemical structure that has never been FDA approved before and usually meets a previously unmet medical need.

In 2017, these novel drug approvals were accompanied by an influx of specialty and brand-name drugs to the market – many treating common chronic conditions like diabetes, asthma and RA.

It is a very exciting time in the healthcare world as these new drugs significantly advance patient care. However, these treatments come at a cost… literally.

This is not a comprehensive list of new-to-market drugs, and does not include all 46 novel drugs, but is a snapshot of key 2017 FDA approvals.

It is hard to predict what the FDA and drug manufacturers will do in 2018. However, we should expect even more high-cost drugs to be approved and available for members.

Hopefully these will be accompanied by the influx of generics and biosimilars to the market – which may help off-set rising drug costs.

One thing we know for sure is that managing drug costs will continue to be key. We employ cost-management strategies such as:

  • Formulary management

  • Prior authorizations

  • Step-therapy programs

  • Regulation of copay cards

All of these strategies will be foundational in conserving costs.

Drug
Approval Date
Approved Use(s)
Estimated Annual Cost
Notes
Hemlibra

 

(emicizumab)

11/16/17 Hemophilia A with FVIII inhibitors $450,000  
Mepsevii

 

(vestronidase alfa-vjbk)

11/15/17 Mucopolysaccharidosis VII (MPS VII, Sly syndrome) $375,000  
Fasenra

 

(benralizumab)

11/14/17 Severe asthma (add-on treatment) $30,000  
Yescarta

 

(axicabtagene ciloleucel)

10/18/17 B-cell lymphoma $370,000  
Verzenio

 

(abemaciclib)

9/28/17 Breast cancer $130,000  
Aliqopa

 

(copanlisib)

9/14/17 Relapsed follicular lymphoma $160,000  
Kymriah

 

(tisagenlecleucel)

8/30/17 Acute lymphocytic leukemia $475,000 per treatment First gene therapy ever approved in the US
Bespona

 

(inotuzumab ozogamicin)

8/17/17 Relapsed or refractory acute lymphoblastic leukemia $170,000

 

 

 
Idhifa

 

(enasidenib)

8/1/17 Relapsed or refractory acute myeloid leukemia $280,000

 

 

 
Vosevi

 

(sofosbuvir, velpatasvir, voxilaprevir)

7/18/17 Hepatitis C $75,000 for 3-month treatment  
Nerlynx

 

(neratinib maleate)

7/17/17 Reduce risk of breast cancer returning $125,000  
Tremfya

 

(guselkumab)

7/13/17 Moderate-to-severe plaque psoriasis

 

 

$58,000  
Endari

 

(L-gultamine)

7/7/17 Sickle cell disease $11,000 – $18,000 Second drug approved for Sickle Cell in the US
Haegarda

 

(C1 esterase inhibitor)

6/22/17 Hereditary angioedema $400,000  
Fibryna

 

(fibrinogen)

6/7/17 Congenital fibrinogen deficiency n/a Pending launch date
Rebinyn

 

(coagulation factor IX)

5/31/17 Hemophilia B n/a Expected launch early 2018
Kevzara

 

(sarilumab)

5/22/17 Rheumatoid arthritis $39,000 Second-line agent
Radicava

 

(edaravone)

5/5/17 ALS $145,000 Second drug ever approved for ALS
Ryadapt

 

(midostaurin)

4/28/17 Acute myeloid leukemia $180,000  
Brineura

 

(cerliponase alfa)

4/27/17 Batten disease

 

 

$700,000 Very rare, inherited condition
Ingrezza

 

(valbenazine)

4/11/17 Tardive dyskinesia $64,000 – $128,000 depending on dose  
Ocrevus

 

(ocrelizumab)

3/28/17 Multiple sclerosis $65,000 (~20% less than current treatments)  
Dupixent

 

(dupilumab)

3/28/17 Moderate-to-severe eczema $37,000  
Zejula

 

(niraparid)

3/27/17 Epithelial ovarian, fallopian tube or primary peritoneal cancers $160,000  
Bavencio

 

(avelumab)

3/23/17 Merkel cell carcinoma $150,000  
Kisqali

 

(ribociclib)

3/13/17 Breast cancer $130,000

 

 

 

Key sources:

Add new comment

Plain text

  • No HTML tags allowed.
  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.